[Pomalidomide combined with dexamethasone in multiple myeloma]
Virgilio S, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A.
Record ID 32018001436
Spanish
Original Title:
Pomalidomida asociado a dexametasona en mieloma múltiple en recaída o refractario
Authors' recommendations:
CONCLUSIONS
No direct evidence comparing pomalidomide in combination with low-dose dexamethasone with other current third line therapies in patients with refractory or relapsed multiple myeloma has been found. Moderate-quality evidence suggests that treatment with pomalidomide in combination with low-dose dexamethasone in adult patients with relapsed multiple myeloma or refractory to lenalidomide and/or bortezomib, when compared with high-dose dexamethasone might improve both overall survival and progression-free survival, and the rate of disease remission.
The clinical practice guidelines consulted recommend treatment with pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma as third-line treatment.
The coverage policies consulted from public and private sponsors from Europe and the United States cover it. As regards Latin America, the public sponsors consulted do not cover the technology assessed to be used as third-line treatment.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Multiple Myeloma
- Dexamethasone
- Angiogenesis Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Thalidomide
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.